151 related articles for article (PubMed ID: 22832131)
1. Patterns of mitochondrial DNA damage in blood and brain tissues of a transgenic mouse model of Machado-Joseph disease.
Kazachkova N; Raposo M; Montiel R; Cymbron T; Bettencourt C; Silva-Fernandes A; Silva S; Maciel P; Lima M
Neurodegener Dis; 2013; 11(4):206-14. PubMed ID: 22832131
[TBL] [Abstract][Full Text] [Related]
2. Differential mtDNA damage patterns in a transgenic mouse model of Machado-Joseph disease (MJD/SCA3).
Ramos A; Kazachkova N; Silva F; Maciel P; Silva-Fernandes A; Duarte-Silva S; Santos C; Lima M
J Mol Neurosci; 2015 Feb; 55(2):449-53. PubMed ID: 25001003
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of Mitochondrial DNA Common Deletion Since The Preataxic Stage of Machado-Joseph Disease.
Raposo M; Ramos A; Santos C; Kazachkova N; Teixeira B; Bettencourt C; Lima M
Mol Neurobiol; 2019 Jan; 56(1):119-124. PubMed ID: 29679261
[TBL] [Abstract][Full Text] [Related]
4. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial DNA haplogroups and age at onset of Machado-Joseph disease/spinocerebellar ataxia type 3: a study in patients from multiple populations.
Ramos A; Planchat M; Vieira Melo AR; Raposo M; Shamim U; Suroliya V; Srivastava AK; Faruq M; Morino H; Ohsawa R; Kawakami H; Bannach Jardim L; Saraiva-Pereira ML; Vasconcelos J; Santos C; Lima M
Eur J Neurol; 2019 Mar; 26(3):506-512. PubMed ID: 30414314
[TBL] [Abstract][Full Text] [Related]
6. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
Ashraf NS; Duarte-Silva S; Shaw ED; Maciel P; Paulson HL; Teixeira-Castro A; Costa MDC
Mol Neurobiol; 2019 May; 56(5):3690-3701. PubMed ID: 30187384
[TBL] [Abstract][Full Text] [Related]
7. Tissue-Specific Vulnerability to Apoptosis in Machado-Joseph Disease.
Ferreira AF; Raposo M; Shaw ED; Ashraf NS; Medeiros F; Brilhante MF; Perkins M; Vasconcelos J; Kay T; Costa MDC; Lima M
Cells; 2023 May; 12(10):. PubMed ID: 37408238
[TBL] [Abstract][Full Text] [Related]
8. The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples.
Duarte Lobo D; Nobre RJ; Oliveira Miranda C; Pereira D; Castelhano J; Sereno J; Koeppen A; Castelo-Branco M; Pereira de Almeida L
Acta Neuropathol Commun; 2020 Aug; 8(1):152. PubMed ID: 32867861
[TBL] [Abstract][Full Text] [Related]
9. Machado Joseph disease severity is linked with gut microbiota alterations in transgenic mice.
Gamage HKAH; Robinson KJ; Luu L; Paulsen IT; Laird AS
Neurobiol Dis; 2023 Apr; 179():106051. PubMed ID: 36822548
[TBL] [Abstract][Full Text] [Related]
10. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
Griffin JL; Cemal CK; Pook MA
Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Dysfunction and Decreased Cytochrome
Almeida F; Ferreira IL; Naia L; Marinho D; Vilaça-Ferreira AC; Costa MD; Duarte-Silva S; Maciel P; Rego AC
Cells; 2023 Oct; 12(19):. PubMed ID: 37830611
[TBL] [Abstract][Full Text] [Related]
12. Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3/MJD Mouse.
Wiatr K; Piasecki P; Marczak Ł; Wojciechowski P; Kurkowiak M; Płoski R; Rydzanicz M; Handschuh L; Jungverdorben J; Brüstle O; Figlerowicz M; Figiel M
Mol Neurobiol; 2019 Dec; 56(12):8168-8202. PubMed ID: 31201651
[TBL] [Abstract][Full Text] [Related]
13. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
14. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
Gonçalves N; Simões AT; Cunha RA; de Almeida LP
Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease.
Matilla T; McCall A; Subramony SH; Zoghbi HY
Ann Neurol; 1995 Jul; 38(1):68-72. PubMed ID: 7611728
[TBL] [Abstract][Full Text] [Related]
16. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
[TBL] [Abstract][Full Text] [Related]
17. Towards the Identification of Molecular Biomarkers of Spinocerebellar Ataxia Type 3 (SCA3)/Machado-Joseph Disease (MJD).
Lima M; Raposo M
Adv Exp Med Biol; 2018; 1049():309-319. PubMed ID: 29427111
[TBL] [Abstract][Full Text] [Related]
18. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia.
Ranum LP; Lundgren JK; Schut LJ; Ahrens MJ; Perlman S; Aita J; Bird TD; Gomez C; Orr HT
Am J Hum Genet; 1995 Sep; 57(3):603-8. PubMed ID: 7668288
[TBL] [Abstract][Full Text] [Related]
19. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
